Janssen to Develop Assays on Biocartis MDx Platform
January 10, 2011
Janssen to Develop Assays on Biocartis MDx Platform
Janssen and J&J's Ortho-Clinical Diagnostics group have worldwide exclusive rights to develop and commercialize assays on the Biocartis platform in the fields of neurological disease and certain viral infectious diseases.
Full-text access for registered users only.
Existing users login here.
New to GenomeWeb? Register here quickly for free access.
New to GenomeWeb? Register here quickly for free access.
Related Stories
- J&J's Janssen Pharmaceutica to Develop MDx Assays for Biocartis' Integrated NAT Platform
January 13, 2011 / PCR Insider - OICR to Launch Prostate Marker Clinical Trials with Janssen
April 22, 2013 / GenomeWeb Daily News - J&J Tests WGS of Rheumatoid Arthritis Patients to ID Markers of Drug Response, Predisposition Genes
April 17, 2013 / Clinical Sequencing News - Following Management Changes, Nanosphere Reports Revenue Growth, but Shortfalls in Dx Placements
February 26, 2013 / BioArray News - Flemish Government Provides $2.5M to Biocartis to Develop Cancer Tests
February 25, 2013 / GenomeWeb Daily News